Novel Therapeutic Agents in Waldenström’s Macroglobulinemia

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström’s macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and hist...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ghobrial, Irene M., Leleu, Xavier, Azab, Abdel Kareem, Runnels, Judith, Jia, Xiaoying, Ngo, Hai, Melhem, Molly, Azab, Feda, Sacco, Antonio, Quang, Phong, Burwick, Nicholas, Moreau, Anne-Sophie, Husu, Emanuel, Farag, Mena, Roccaro, Aldo
Formato: Artigo
Lenguaje:Inglês
Publicado: 2009
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3133646/
https://ncbi.nlm.nih.gov/pubmed/19362982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLM.2009.n.022
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares